RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
Regulatory Focus™ > News Articles > 2020 > 4 > Recon: Abbott beats quarterly profit estimates; UK approves Penlon ventilator for COVID-19

Recon: Abbott beats quarterly profit estimates; UK approves Penlon ventilator for COVID-19

Posted 16 April 2020 | By Michael Mezher 

Recon: Abbott beats quarterly profit estimates; UK approves Penlon ventilator for COVID-19

Editor’s note: Regulatory Recon will be undergoing some changes in the coming weeks as we fine tune its content and presentation to better align with the topics and industries it covers. We value your input as we adapt Recon going forward. Please write to news@raps.org if you have any comments or suggestions.
 
In Focus: US
  • Chaotic search for coronavirus treatments undermines efforts, experts say (Washington Post)
  • House Speaker Pelosi calls Trump WHO decision senseless, dangerous (Reuters)
  • Trump Admin. Officials Warned Against Halting Funding to WHO - Leaked Memo (ProPublica)
  • White House snubs Azar, installs Trump loyalist Michael Caputo as HHS spokesperson (Politico)
  • House Progressives Seek to Bar Vaccine, Treatment Exclusivity (Bloomberg) (Law360)
  • US Senate Democrats seek $30 billion for national coronavirus testing (Reuters)
  • Americans aren't ready to go back to normal after a coronavirus reopening (Axios) (Reuters)
  • Testing Falls Woefully Short as Trump Seeks an End to Stay-at-Home Orders (NYTimes)
  • US races to stock up on dialysis supplies as kidney failure ravages virus patients (Politico)
  • Sanofi teams up with US firm Luminostics on developing COVID-19 testing app (Reuters)
  • FDA Grants Approval of Jelmyto to Urogen Pharma (Bloomberg Law) (Endpoints) (FDA) (Press)
  • Gilead is Said to Hold Arcus Stake Talks, Spurring 54% Rally (Bloomberg) (Endpoints)
  • Biogen joins consortium for building COVID-19 'biobank' (Reuters)
  • Abbott beats quarterly profit, but pulls forecast on coronavirus concerns (Reuters)
  • Half of prescriptions needed for Covid-19 patients on ventilators are going unfilled (STAT)
In Focus: International
  • 'We Alerted The World' To Coronavirus On Jan. 5, WHO Says In Response To US (NPR) (NYTimes)
  • Europe coronavirus cases reach almost 1 million, coming weeks 'critical': WHO (Reuters)
  • Japan, China Vie to Be Global Supplier of Unproven Coronavirus Drug (WSJ)
  • Aurobindo’s regulatory woes cast a shadow on strong fundamentals (Economic Times)
  • Aid groups ask UK gov to stop pharma 'profiteering' from COVID-19 (PharmaTimes)
  • Canadian hospitals prepare to sterilize, re-use N95 masks if supplies dwindle (Reuters)
  • Penlon ventilator receives UK approval in battle against coronavirus (Reuters)
  • Israel retrofits home-use respirators into ventilators to treat coronavirus (Reuters)
  • Gilead Japan to Seek Early Remdesivir Filing If Initial Data Prove Positive: Development Chief (PharmaJapan)
  • PMDA: Novartis’ Flawed, Delayed Responses in Zolgensma Review ‘Extremely Unusual’ (PharmaJapan)
Coronavirus Pandemic
  • Coronavirus Vaccine Prospects (In the Pipeline)
  • Fauci: Coronavirus vaccines could be ready sooner than expected (Axios)
  • Coronavirus: Drugs to be tested on lungs of ICU patients (BBC)
  • Roivant begins giving experimental COVID-19 drug to first US patients (Reuters)
  • Coronavirus pandemic threatens to take crushing toll on rural areas, data show (STAT)
  • Private labs say demand for coronavirus tests is down and they can test more people who aren't as sick (NBC)
  • Here’s What We Know about the Most Touted Drugs Tested for COVID-19 (Scientific American)
  • Scientists tap CRISPR’s search-and-detect skills to create a rapid Covid-19 test (STAT)
  • Blood clots in severe Covid-19 patients leave clinicians with clues about the illness — but no proven treatments (STAT)
  • Simply speaking could transmit coronavirus, new study suggests (STAT) (NEJM)
  • Gay men still unable to donate blood and plasma despite new FDA guidelines. Here's why. (NBC)
  • US coronavirus deaths increase by record amount for second straight day: Reuters tally (Reuters)
  • US coronavirus deaths march higher to over 31,000: Reuters tally (Reuters)
  • The CDC and WHO Have Already Said Mosquitoes Don’t Spread Coronavirus. Now USDA Will Study It, Too. (ProPublica)
  • Australia to retain coronavirus curbs for at least another four weeks (Reuters)
  • Germany plans partial reopening of shops and schools: sources (Reuters)
  • Britain probably reaching virus peak, says England's Chief Medical Officer (Reuters)
  • French coronavirus toll jumps by record 1,438 deaths (Reuters)
  • Australia to keep coronavirus restrictions for four more weeks despite success (Reuters)
  • As Brazil's COVID-19 testing lags, available labs go unused (Reuters)
  • Supplies for coronavirus field hospital held up at US-Mexico border (Reuters)
  • Mexico president says UN slow in ensuring access to medical gear amid coronavirus (Reuters)
  • Coronavirus (COVID-19) Update: Daily Roundup April 15, 2020 (FDA)
Pharma & Biotech
  • Is It Safe to Take That Medication While Breastfeeding? (NYTimes)
  • Remarks by Dr. Hahn to the 2020 Rx Drug Abuse and Heroin Summit (FDA)
  • Leo Pharma licenses global rights from two Asian biotechs (PMLive)
  • Sumitomo subsidiary flashes new way of treating schizophrenia in PhII trial (Endpoints) (Science Mag)
  • Evidence from Pragmatic Trials during Routine Care — Slouching toward a Learning Health System (NEJM)
  • Amneal yanks ulcer drug off US shelves on fears of carcinogen contamination (Fierce)
  • Delayed Advisory Committees Need Not Worry Sponsors Too Much (Pink Sheet)
  • Regeneron gets FDA priority review for Ebola sibling of COVID-19 prospect (Fierce)
  • Covid medicine: Dr Reddy’s Laboratories begins work on Gilead drug clone (Economic Times)
  • Novo Nordisk expands 90-day free insulin program to workers affected by COVID-19 (Fierce)
  • CARES Act Will Accelerate OTC Drug Development (Law360)
  • Drug Cos. May Find Real-World Evidence Cuts Both Ways (Law360)
  • Abundant funding, sparse data: San Francisco startup backs 'real world' model for rare disease drug development (Endpoints)
  • Interim data on Vir's Alnylam-partnered RNAi hep B drug suggest efficacy is broadly on par with J&J, Arrowhead rival — analysts (Endpoints)
  • Pascal Soriot, lamenter of low pay, faces investor revolt for being overcompensated (Endpoints)
  • Galapagos finds Polish partner for inflammation drugs; Zai Lab's Zejula app gets speedy review in China (Endpoints)
  • Top FDA Drug Compliance Concerns during 2019 Included OTCs, Supply Chain Information Flow, Compounding, and Genotoxic Impurities (IPQ)
  • The European research-based pharmaceutical industry’s commitment to tackling the coronavirus pandemic (EFPIA)
Medtech
  • Boston Scientific to begin selling cheaper ventilator alternative (MedtechDive)
  • Philips launches scaled-down ventilator, inks production deals to boost output (MedtechDive)
  • Dexcom gets FDA permission to use continuous glucose monitors on hospitalized COVID-19 patients (San Diego Union-Tribune)
  • CMS doubles Medicare payment for coronavirus diagnostic lab tests (MedtechDive)
Government & Regulatory
  • Pharmacy chains gain a ‘solid’ victory in opioid litigation, but aren’t off the hook yet (STAT)
  • Utah bill would clear the way for experimental drugs to treat COVID-19 (Salt Lake Tribune)
  • Pandemic will delay blockbuster trial of ex-Theranos CEO Elizabeth Holmes (STAT) (CNBC)
  • PTAB Axes University Of Chicago Cancer Treatment Patent (Law360)
  • Federal Court of Australia grants interim injunction to prevent advertising by Evolution Supplements Australia (TGA)
  • Medical device labelling obligations (TGA)
  • Regulation of Personal Protective Equipment and COVID-19 (TGA)
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
 
A story's inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe